Short Interest in Evogene Ltd. (NASDAQ:EVGN) Grows By 28.7%

Evogene Ltd. (NASDAQ:EVGN) saw a significant growth in short interest during the month of March. As of March 13th, there was short interest totaling 242,174 shares, a growth of 28.7% from the February 26th total of 188,218 shares. Currently, 4.9% of the company’s shares are short sold. Based on an average daily volume of 188,709 shares, the days-to-cover ratio is currently 1.3 days.

Evogene Price Performance

Shares of NASDAQ:EVGN opened at $0.82 on Monday. The stock’s 50-day moving average is $0.92 and its 200 day moving average is $1.08. The company has a market cap of $4.40 million, a PE ratio of -0.70 and a beta of 1.36. Evogene has a 1 year low of $0.73 and a 1 year high of $2.42.

Evogene (NASDAQ:EVGN) last released its quarterly earnings data on Saturday, February 14th. The biotechnology company reported ($0.61) earnings per share for the quarter. The business had revenue of $0.31 million during the quarter. Evogene had a negative return on equity of 121.44% and a negative net margin of 214.57%.

Institutional Trading of Evogene

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EVGN. Jane Street Group LLC increased its position in Evogene by 58.0% during the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 12,387 shares during the period. XTX Topco Ltd purchased a new stake in shares of Evogene in the 4th quarter worth about $25,000. Finally, Citadel Advisors LLC boosted its stake in shares of Evogene by 169.4% during the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 36,206 shares in the last quarter. Hedge funds and other institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.